Redefining Veterinary Therapeutics
A low-risk, high-reward strategy for creating first-in-class medicines for our pets.
1 in 3
Senior cats affected by Chronic Kidney Disease, a leading cause of death.
$2B+
Annual serviceable market with no effective disease-modifying treatments.
>60%
Reduction in development risk and cost vs. new molecule discovery.
The Unmet Need is a
Blockbuster Opportunity.
Feline Chronic Kidney Disease is a devastating silent epidemic. Current treatments only manage symptoms, leaving veterinarians and pet owners desperate for a real solution. We are answering that call with Renavicta™, a first-in-class therapeutic designed to fundamentally change the standard of care.
The NouvoPont Advantage.
Our model is built on intelligent innovation, not high-risk discovery. By strategically reformulating a proven human therapeutic, we create immense value while dramatically de-risking the entire development process.
Proven Science
We leverage molecules with established safety and efficacy profiles from human medicine, eliminating the guesswork of early-stage research.
Capital Efficiency
This strategy bypasses years of costly discovery and toxicology studies, allowing us to reach critical milestones with a fraction of the typical investment.
Accelerated Pathway
By using existing data, our regulatory timeline is significantly compressed, enabling a faster path to market and to a high-value exit for our investors.
Our Pipeline.
We apply our unique development model to address the most significant unmet needs in veterinary medicine, starting with chronic kidney disease and oncology.
LEAD PROGRAM
Renavicta™
Our first therapeutic is a proprietary, palatable oral liquid designed to be the first disease-modifying treatment for feline Chronic Kidney Disease.
ONCOLOGY PLATFORM
Targeting Canine Lymphoma
Our next-generation program leverages advanced antibody engineering to create safer, more precise immunotherapies for canine lymphoma.
Advanced Antibody Engineering
Our platform develops novel antibody constructs designed to precisely target cancer cells while sparing healthy tissue. This approach has the potential to offer a significantly improved safety profile compared to traditional chemotherapy, enhancing quality of life during treatment.
Large Unmet Need
Canine lymphoma is one of the most common cancers in dogs. Despite advances, there remains a significant need for more effective and less toxic treatment options. Our platform is positioned to deliver a new standard of care for this widespread and life-threatening disease.
A Clear Path to a Strategic Exit.
Our assets are designed to be highly attractive acquisition targets for the largest players in animal health, who are actively seeking de-risked, first-in-class products to bolster their portfolios.
Zoetis
Elanco
Boehringer Ingelheim
Merck Animal Health